HC Wainwright Reaffirms “Buy” Rating for Dyadic International (NASDAQ:DYAI)

Dyadic International (NASDAQ:DYAI)‘s stock had its “buy” rating reaffirmed by analysts at HC Wainwright in a research report issued to clients and investors on Thursday,Benzinga reports. They currently have a $6.00 target price on the biotechnology company’s stock. HC Wainwright’s price target points to a potential upside of 435.71% from the stock’s current price.

Dyadic International Stock Down 1.8 %

DYAI stock opened at $1.12 on Thursday. The company has a market cap of $33.02 million, a price-to-earnings ratio of -4.87 and a beta of 0.72. Dyadic International has a twelve month low of $0.93 and a twelve month high of $2.67. The business has a 50 day moving average price of $1.13 and a two-hundred day moving average price of $1.42. The company has a quick ratio of 5.39, a current ratio of 5.39 and a debt-to-equity ratio of 1.72.

Dyadic International (NASDAQ:DYAI) last released its earnings results on Tuesday, November 12th. The biotechnology company reported ($0.01) earnings per share for the quarter, beating the consensus estimate of ($0.07) by $0.06. Dyadic International had a negative net margin of 188.09% and a negative return on equity of 140.01%. The business had revenue of $1.96 million during the quarter, compared to analysts’ expectations of $1.05 million. During the same period last year, the business earned ($0.06) earnings per share. Analysts anticipate that Dyadic International will post -0.28 EPS for the current fiscal year.

Institutional Investors Weigh In On Dyadic International

A hedge fund recently raised its stake in Dyadic International stock. Chapin Davis Inc. lifted its holdings in shares of Dyadic International, Inc. (NASDAQ:DYAI) by 2.5% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 847,301 shares of the biotechnology company’s stock after acquiring an additional 21,000 shares during the quarter. Chapin Davis Inc. owned approximately 2.90% of Dyadic International worth $1,254,000 as of its most recent SEC filing. Institutional investors own 27.95% of the company’s stock.

Dyadic International Company Profile

Dyadic International, Inc, a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health.